Invitae

CMS's move to restrict coverage could limit test access for early-stage cancer patients and negatively impact lab revenues.

In an effort to lift patient access barriers, the company is launching a model whereby consumers will be able to initiate test orders online.

In a preliminary financial report, the company said it is expecting revenues of more than $144 million and to have tested more than 300,000 samples.

The index fell more than 11 percent in December, underperforming the Dow and the Nasdaq, but performing on par with the Nasdaq Biotechnology Index.

The investment bank called Genomic Health a leader in diagnostic testing and said Invitae will benefit from growth trends in the genetic testing sector.

Missed a Few

Newsday reports that breast cancer genetic testing guidelines for are out of date and may miss individuals.

The company accessioned approximately 78,000 samples in Q3 2018, up 95 percent from the year-ago quarter when it accessioned 40,000 samples..

Through the Alnylam Act program, patients suspected of having the rare disease or with a family history of the illness will receive testing at no cost.

The company plans to use the technology, originally developed by Good Start Genetics, to offer sample preparation solutions and data analysis for NGS.

Pages

Reuters reports that UK researchers are using gene-editing tools to develop flu-resistant chickens.

Nature calls for genomics to become part of the World Health Organization's cholera surveillance approach.

Vox explores a proposal to institute a lottery system to award grant funds.

In Genome Biology this week: gut microbiome study of individuals from Tanzania and Botswana, sixth version of the Network of Cancer Genes database, and more.